Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Annika, Ålgars"'
Autor:
Sampsa Kinos, Helga Hagman, Päivi Halonen, Leena-Maija Soveri, Mary O'Reilly, Per Pfeiffer, Jan-Erik Frödin, Halfdan Sorbye, Eetu Heervä, Gabor Liposits, Raija Kallio, Annika Ålgars, Raija Ristamäki, Tapio Salminen, Maarit Bärlund, Carl-Henrik Shah, Ray McDermott, Rebecka Röckert, Petra Flygare, Johannes Kwakman, Arco Teske, Cornelis Punt, Bengt Glimelius, Pia Österlund
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of
Externí odkaz:
https://doaj.org/article/340dd2f28c5441ddaf0adaf8e0022afa
Autor:
Vesa, Väliaho, Jaana, Mäkitalo, Ia, Kohonen, Anu, Carpelan, Heikki, Minn, Raija, Ristamäki, Annika, Ålgars, Eetu, Heervä
Publikováno v:
In Clinical and Translational Radiation Oncology September 2023 42
Autor:
Emerik Osterlund, Ari Ristimäki, Soili Kytölä, Teijo Kuopio, Eetu Heervä, Timo Muhonen, Päivi Halonen, Raija Kallio, Leena-Maija Soveri, Jari Sundström, Mauri Keinänen, Annika Ålgars, Raija Ristamäki, Halfdan Sorbye, Per Pfeiffer, Luís Nunes, Tapio Salminen, Annamarja Lamminmäki, Markus J. Mäkinen, Tobias Sjöblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundKRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this sp
Externí odkaz:
https://doaj.org/article/decb120b6a4a470ea68f4e7d8f7c7d6d
Autor:
Pia Osterlund, Tapio Salminen, MD, Leena-Maija Soveri, MD, Raija Kallio, MD, Ilmo Kellokumpu, MD, Annamarja Lamminmäki, MD, Päivi Halonen, MD, Raija Ristamäki, MD, Eila Lantto, MD, Aki Uutela, MD, Emerik Osterlund, MD, Ali Ovissi, MD, Arno Nordin, MD, Eetu Heervä, MD, Kaisa Lehtomäki, MD, Jari Räsänen, MD, Maija Murashev, MD, Laura Aroviita, MD, Antti Jekunen, Prof, Reneé Lindvall-Andersson, MD, Paul Nyandoto, MD, Juha Kononen, MD, Anna Lepistö, MD, Tuija Poussa, MSc, Timo Muhonen, MD, Annika Ålgars, MD, Helena Isoniemi, Prof
Publikováno v:
The Lancet Regional Health. Europe, Vol 3, Iss , Pp 100049- (2021)
Background: Resection of colorectal cancer (CRC) metastases provides good survival but is probably underused in real-world practice. Methods: A prospective Finnish nationwide study enrolled treatable metastatic CRC patients. The intervention was the
Externí odkaz:
https://doaj.org/article/242b5d11ce0240999caa17287c9963a7
Autor:
Kaisa Lehtomäki, Leena-Maija Soveri, Emerik Osterlund, Annamarja Lamminmäki, Aki Uutela, Eetu Heervä, Päivi Halonen, Hanna Stedt, Sonja Aho, Timo Muhonen, Annika Ålgars, Tapio Salminen, Raija Kallio, Arno Nordin, Laura Aroviita, Paul Nyandoto, Juha Kononen, Bengt Glimelius, Raija Ristamäki, Helena Isoniemi, Pia Osterlund
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 10; Pages: 3541
Older adults are underrepresented in metastatic colorectal cancer (mCRC) studies and thus may not receive optimal treatment, especially not metastasectomies. The prospective Finnish real-life RAXO-study included 1086 any organ mCRC patients. We asses
Autor:
Raija Kallio, Leena-Maija Soveri, Raija Ristamäki, Jari Räsänen, I. Kellokumpu, Arno Nordin, Ali Ovissi, P. Halonen, Helena Isoniemi, Annika Ålgars, Y Vaalavuo, Annamarja Lamminmäki, Maija Lavonius, Eila Lantto, Aki Uutela, T. Salminen, Pia Österlund, H Karjula, J Kosunen
Publikováno v:
British Journal of Surgery. 108:817-825
Background Metastasectomy is probably underused in metastatic colorectal cancer. The aim of this study was to investigate the effect of centralized repeated assessment on resectability rate of liver metastases. Methods The prospective RAXO study was
Autor:
Kaisa Lehtomäki, Hanna P. Stedt, Emerik Osterlund, Timo Muhonen, Leena-Maija Soveri, Päivi Halonen, Tapio K. Salminen, Juha Kononen, Raija Kallio, Annika Ålgars, Eetu Heervä, Annamarja Lamminmäki, Aki Uutela, Arno Nordin, Juho Lehto, Tiina Saarto, Harri Sintonen, Pirkko-Liisa Kellokumpu-Lehtinen, Raija Ristamäki, Bengt Glimelius, Helena Isoniemi, Pia Osterlund
Publikováno v:
Cancers; Volume 14; Issue 7; Pages: 1713
Simple Summary Metastatic colorectal cancer is the second most common cause of cancer death. Long-term survival and cure can be achieved after intensive treatments, including metastasectomy, i.e., the removal of all metastases. We wanted to clarify w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c25603471d7b6182006374be9c224ad0
http://hdl.handle.net/10138/343237
http://hdl.handle.net/10138/343237
Autor:
Samu Kurki, A. Carpelan, Olli Carpén, Raija Ristamäki, Eetu Heervä, Jari Sundström, Vesa Väliaho, Pia Österlund, Arto Rantala, Annika Ålgars, Heikki Minn, T. Salminen, Lasse Nieminen, Heikki Huhtinen
Publikováno v:
Acta Oncologica. 59:1503-1507
High-risk stage II colon cancer is defined in European and American guidelines as the presence of at least one of the following high-risk factors: T4 stage, tumor differentiation grade 3, bowel obs...
Autor:
Laura Lehtinen, Raija Ristamäki, Vanina D. Heuser, Annika Ålgars, Eva-Maria Birkman, Olli Carpén, Naziha Mansuri, Minnamaija Lintunen, Jari Sundström
Publikováno v:
Virchows Archiv
While host immune response is likely to be important for the prognosis of gastric cancer patients, detailed information on the T lymphocyte infiltration in different gastric cancer subtypes is lacking. Here, we studied the presence of CD3, CD8, and F
Autor:
Aki Uutela, Emerik Osterlund, Päivi Halonen, Raija Kallio, Annika Ålgars, Tapio Salminen, Annamarja Lamminmäki, Leena-Maija Soveri, Raija Ristamäki, Kaisa Lehtomäki, Hanna Stedt, Eetu Heervä, Timo Muhonen, Juha Kononen, Arno Nordin, Ali Ovissi, Soili Kytölä, Mauri Keinänen, Jari Sundström, Lasse Nieminen, Markus J. Mäkinen, Teijo Kuopio, Ari Ristimäki, Helena Isoniemi, Pia Osterlund
Background Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status, but their effects on resectability and conversion rates have not been extensively studied. Methods This substudy of the prospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eebc54b4b9dad91d9d71a2bfc7447fa
http://urn.fi/URN:NBN:fi:jyu-202206163431
http://urn.fi/URN:NBN:fi:jyu-202206163431